THE EXTENT OF THE USE OF MEDICINES USED IN HYPERTENSIVE CRISIS AND THE RELEVANCE OF THEIR IMPROVEMENT

A significant rise in BP coupled with acute, A-HMOD to the heart, brain, retina, kidneys, and major arteries characterizes hypertensive emergencies (HE), which are high cardiovascular risk circumstances. Since blood pressure readings by themselves cannot reliably indicate the existence of HE, the first line of treatment for acute severe hypertension should be to look for A-HMOD. To reduce the risk of complications, enhance patient outcomes, and limit and encourage the regression of end-organ damage, a prompt therapeutic intervention is essential. The kind of A-HMOD, particular drug pharmacokinetics, adverse drug effects, and comorbidities all influence drug therapy for HE, target blood pressure, and the rate at which blood pressure decreases. Consequently, a customized strategy is necessary. For the majority of HE, there is currently insufficient evidence to support effective treatment approaches. In addition to reviewing contemporary pharmacological approaches, this article offers a methodical, evidence-based approach to the treatment of HE. The treatment of acute hypertension differs based on the presentation and local expertise and available resources. There is frequently a dearth of high-quality evidence, or when it does exist, it does not consistently support certain medication regimens or rates of blood pressure reduction. Finally, after speaking with the BIHS and considering the available evidence as well as any areas where there was disagreement, comments were made. A uniform, evidence-based approach to provide high-quality care to patients is the aim of the proposed set of guidelines for the management of acute hypertensive conditions.